Literature DB >> 11318594

Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.

J Szabó1, L Cervenák, F D Tóth, Z Prohászka, L Horváth, K Kerekes, Z Beck, A Bácsi, A Erdei, E I Peerschke, G Füst, B Ghebrehiwet.   

Abstract

C1q and the outer envelope protein of HIV, gp120, have several structural and functional similarities. Therefore, it is plausible to assume that proteins that are able to interact with C1q may also interact with isolated gp120 as well as the whole HIV-1 virus. Based on this hypothesis, we studied the potential ability of the recombinant form of the 33-kDa protein, which binds to the globular "heads" of C1q (gC1q-R/p33), to inhibit the growth of different HIV-1 strains in cell cultures. gC1q-R/p33 was found to effectively and dose-dependently inhibit the production of one T-lymphotropic (X4) and one macrophage-tropic (R5) strain in human T cell lines (MT-4 and H9) and human monocyte-derived macrophage cultures, respectively. At a concentration range of 5-25 microg/ml, gC1q-R caused a marked and prolonged suppression of virus production. The extent of inhibition was enhanced when gC1q-R was first incubated with and then removed from the target cell cultures before virus infection, compared to that when the cells were infected with gC1q-R-HIV mixtures. The extent of inhibition was comparable to that of the Leu3a anti-CD4 antibody. Addition of gC1q-R to the cell cultures on day 1 or 2 after infection induced markedly less inhibition of HIV-1 growth than pretreatment of the cells just before or together with the infective HIV strains. In ELISA experiments, gC1q-R did not bind to a solid-phase recombinant gp120 while strong and dose-dependent binding of gC1q-R to solid-phase CD4 was observed. Our present findings indicate that gC1q-R is an effective inhibitor of HIV-1 infection, which prevents viral entry by blocking the interaction between CD4 and gp120. Since gC1q-R is a human protein, it is most probably not antigenic in humans. It would seem logical, therefore, to consider gC1q-R or its fragments involved in the CD4 binding as potential therapeutic agents. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11318594     DOI: 10.1006/clim.2001.5013

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  5 in total

1.  Identification of the gC1qR sites for the HIV-1 viral envelope protein gp41 and the HCV core protein: Implications in viral-specific pathogenesis and therapy.

Authors:  Lina Pednekar; Alisa Valentino; Yan Ji; Nithin Tumma; Christopher Valentino; Adarsh Kadoor; Kinga K Hosszu; Mahalakshmi Ramadass; Richard R Kew; Uday Kishore; Ellinor I B Peerschke; Berhane Ghebrehiwet
Journal:  Mol Immunol       Date:  2016-04-23       Impact factor: 4.407

2.  Complement Protein C1q Interacts with DC-SIGN via Its Globular Domain and Thus May Interfere with HIV-1 Transmission.

Authors:  Lina Pednekar; Hrishikesh Pandit; Basudev Paudyal; Anuvinder Kaur; Maha Ahmed Al-Mozaini; Lubna Kouser; Berhane Ghebrehiwet; Daniel A Mitchell; Taruna Madan; Uday Kishore
Journal:  Front Immunol       Date:  2016-12-22       Impact factor: 7.561

Review 3.  Monocyte Expressed Macromolecular C1 and C1q Receptors as Molecular Sensors of Danger: Implications in SLE.

Authors:  Berhane Ghebrehiwet; Kinga K Hosszu; Alisa Valentino; Yan Ji; Ellinor I B Peerschke
Journal:  Front Immunol       Date:  2014-06-26       Impact factor: 7.561

Review 4.  C-Type Lectin Receptors in Antiviral Immunity and Viral Escape.

Authors:  Marta Bermejo-Jambrina; Julia Eder; Leanne C Helgers; Nina Hertoghs; Bernadien M Nijmeijer; Melissa Stunnenberg; Teunis B H Geijtenbeek
Journal:  Front Immunol       Date:  2018-03-26       Impact factor: 7.561

Review 5.  Complement Proteins as Soluble Pattern Recognition Receptors for Pathogenic Viruses.

Authors:  Valarmathy Murugaiah; Praveen M Varghese; Nazar Beirag; Syreeta De Cordova; Robert B Sim; Uday Kishore
Journal:  Viruses       Date:  2021-05-02       Impact factor: 5.048

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.